A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Financial Summary
| Share Statistics | CDT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.8 | $1,790.4 | 1% |
|
| Shares Out (Mil) | 0.1 | 94.8 | 1% |
|
| Institutional Ownership | 52.7% | 90.0% | 36% |
|
| Float (Mil) | 0.6 | 69.9 | 1% |
|
| Beta | 1.46 | 1.20 | 81% |
|
| Avg Daily Volume (000s) | 77 | 814 | 33% |
|
| Price Change (52-week) |
(99.9%) | 80.2% | 0% |
|
| Growth | CDT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 7.8% | na |
|
| Net Income (5yr) | (79.6%) | (13.7%) | 3% |
|
| EPS (5yr) | na | 0.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CDT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $785 | na |
|
| Net Income (TTM) (Mil) | ($39) | ($14) | 18% |
|
| EPS (TTM) | na | ($0.200) | na |
|
| Operating Cash Flow (TTM) (Mil) | ($14) | $53 | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | ($4) | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $270 | 0% |
|
| Enterprise Value (Q1) (Mil) | $3 | $2,444 | 4% |
|
| Valuation | CDT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.01 | 2.92 | 0% |
|
| P/E | na | 43.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | CDT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 47.6% | na |
|
| Net Margin | na | (2.9%) | na |
|
| ROA | (57.2%) | (2.8%) | 10% |
|
| ROE | (71.0%) | (4.5%) | 12% |
|
| Liabilities to Assets | 17.0% | 43.0% | 11% |
|
| F-Score | 3 | 5 | na |
|
CDT Equity Inc. did not pass any screens on 7/31/2026.
